ArticleNucleic acids research2014
Therapeutic target database update 2014: a resource for targeted therapeutics.
Article in Nucleic acids research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Assessment of the Readiness of Molecular Biomarker-Based Mobile Health Technologies for Healthcare Applications.Scientific reports · 2015Pooled it
- Simulation-guided chemical direct reprogramming informed by temporal cellular conversion processes at the single-cell level.Communications chemistry · 2026Article
- Mechanism-based prediction of drug synergy via network controllability analysis of therapeutic pathways in intractable diseases.iScience · 2026Article
- Integrated network pharmacology, molecular docking, and animal experiments to reveal the potential mechanism of hesperetin on COPD.Scientific reports · 2025Article
- DIRECTEUR: transcriptome-based prediction of small molecules that replace transcription factors for direct cell conversion.Bioinformatics (Oxford, England) · 2024Article
- Hesperetin promotes bladder cancer cells death via the PI3K/AKT pathway by network pharmacology and molecular docking.Scientific reports · 2024Article
- Withdrawn 2.0-update on withdrawn drugs with pharmacovigilance data.Nucleic acids research · 2024Article
- Comprehensive survey of target prediction web servers for Traditional Chinese Medicine.Heliyon · 2023Review
- Relationship between drug targets and drug-signature networks: a network-based genome-wide landscape.BMC medical genomics · 2023Article
- SuperNatural 3.0-a database of natural products and natural product-based derivatives.Nucleic acids research · 2023Article
- Article
- DTI-BERT: Identifying Drug-Target Interactions in Cellular Networking Based on BERT and Deep Learning Method.Frontiers in genetics · 2022Article
- Combination treatment with cisplatin, paclitaxel and olaparib has synergistic and dose reduction potential in ovarian cancer cells.Experimental and therapeutic medicine · 2021Article
- Virus-CKB: an integrated bioinformatics platform and analysis resource for COVID-19 research.Briefings in bioinformatics · 2021Article
- Article
- Study on the mechanisms of compound Kushen injection for the treatment of gastric cancer based on network pharmacology.BMC complementary medicine and therapies · 2020Article
- Potential Molecular Mechanisms of Plantain in the Treatment of Gout and Hyperuricemia Based on Network Pharmacology.Evidence-based complementary and alternative medicine : eCAM · 2020Review
- Systems Biology Approaches to Understanding the Human Immune System.Frontiers in immunology · 2020Article
- Article
- Natural Product Target Network Reveals Potential for Cancer Combination Therapies.Frontiers in pharmacology · 2019Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Here we describe an update of the Therapeutic Target Database (http://bidd.nus.edu.sg/group/ttd/ttd.asp) for better serving the bench-to-clinic communities and for enabling more convenient data access, processing and exchange. Extensive efforts from the research, industry, clinical, regulatory and management communities have been collectively directed at the discovery, investigation, application, monitoring and management of targeted therapeutics. Increasing efforts have been directed at the development of stratified and personalized medicines. These efforts may be facilitated by the knowledge of the efficacy targets and biomarkers of targeted therapeutics. Therefore, we added search tools for using the International Classification of Disease ICD-10-CM and ICD-9-CM codes to retrieve the target, biomarker and drug information (currently enabling the search of almost 900 targets, 1800 biomarkers and 6000 drugs related to 900 disease conditions). We added information of almost 1800 biomarkers for 300 disease conditions and 200 drug scaffolds for 700 drugs. We significantly expanded Therapeutic Target Database data contents to cover >2300 targets (388 successful and 461 clinical trial targets), 20 600 drugs (2003 approved and 3147 clinical trial drugs), 20,000 multitarget agents against almost 400 target-pairs and the activity data of 1400 agents against 300 cell lines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.